GoKawiil
Tech News
Scientists have developed a drug delivery approach that targets specific structures within individual cells rather than simply reaching a cell as a whole. This subcellular precision aims to route therapeutic payloads to particular organelles or compartments where they can act most effectively.
Scientists are developing intranasal vaccines designed to trigger immunity directly in the nose and upper airway, the entry point for many respiratory pathogens. Unlike injected vaccines that mainly prevent severe illness, these formulations aim to stop infection and transmission before a virus can spread further.
Researchers are redesigning drug molecules and delivery systems so a single injection or implant can maintain therapeutic effects for weeks, months, or even years instead of requiring daily dosing. Techniques include chemical modifications that slow drug breakdown, polymer depots, and implantable devices that release medication gradually over extended periods.
A Nature piece argues that even well-designed drugs fail patients if they cannot reach the intended biological target effectively. The commentary highlights delivery mechanisms and targeting accuracy as critical, often underappreciated, factors in therapeutic success.
A Nature editorial argues that a substantial share of prescribed medicines fail to help patients simply because they are not taken as directed. It calls for more research and health-system attention on why patients skip or stop treatments, rather than focusing solely on drug development.
Researchers at the University of Minnesota, led by surgeon Daniel Saltzman, have developed a therapy using genetically modified Salmonella Typhimurium bacteria to carry interleukin-2, an immune-stimulating molecule, straight into tumours. Pancreatic cancer patient John Heller received the experimental treatment after starting chemotherapy for advanced disease, illustrating an early real-world test of the approach.
A Nature feature surveys six novel approaches under development for delivering drugs more precisely and effectively, ranging from advanced nanoparticle carriers to devices designed to target specific tissues. These innovations aim to overcome longstanding challenges such as poor bioavailability, degradation before reaching target sites, and off-target side effects.
Scientists are developing genetically modified bacteria designed to seek out and treat tumors from within the body. The approach relies on engineering microbes to recognize cancerous tissue and deliver therapeutic effects directly at the tumor site.
A group of researchers, including members of the G20 Extraordinary Committee of Independent Experts on Global Inequality convened by South African President Cyril Ramaphosa, has proposed creating an International Panel on Inequality (IPI). The body would function like the Intergovernmental Panel on Climate Change, systematically reviewing evidence on the scale, causes and effects of inequality and assessing which policies actually reduce it. A founding committee has already begun developing the proposal after it was presented to G20 governments earlier this year.
Nature's careers team is organizing a 60-minute webinar examining how doctoral programmes are adjusting to the growing use of AI tools among graduate students, who increasingly rely on them for literature searches, coding, presentations and summarizing papers. Three panellists will discuss the benefits of AI in research alongside concerns that it may weaken essential skills PhD training is meant to instill.
Apple's iOS 27 update overhauls the Home app with Apple Intelligence features, letting it summarize alerts from doorbells and smoke detectors instead of flooding the lock screen with notifications. Cameras gain improved AI-based detection of faces and animals, can stitch together footage of a person moving through multiple rooms, and now record in 4K with AI-generated video descriptions and searchable events. The update also lets users update all Apple TVs at once from the Home app and improves overall app reliability.
An Anthropic employee has left the company, warning that competitive pressure among AI labs is pushing them to build self-improving models that could escape human oversight. The departure reflects growing internal unease about the pace of AI capability development outstripping safety safeguards.